Posted by Michael Wonder on 08 Jun 2017
Bristol-Myers Squibb announces availability of new Orencia (abatacept) subcutaneous administration option for patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis
8 June 2017 - New pre-filled syringe option can be administered at home.
Bristol-Myers Squibb Company announced today the availability of a new FDA approved subcutaneous Orencia administration option for use in patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis.
The new pre-filled syringe offers physicians, patients, and caregivers of these patients the option of Orencia treatment that can be administered at home.
In 2008, Orencia IV was the first FDA-approved IV biologic for use in patients 6 years of age and older with moderately to severely active polyarticular juvenile idioopathic arthritis.
